Literature DB >> 22654459

Lamivudine treatment enabling right hepatectomy for hepatocellular carcinoma in decompensated cirrhosis.

Koichi Honda1, Masataka Seike, Shin-ichiro Maehara, Koichiro Tahara, Hideaki Anai, Akira Moriuchi, Toyokichi Muro.   

Abstract

A 69-year-old man was admitted to our hospital in October 2003, for further examination of two liver tumors. He was diagnosed with hepatocellular carcinoma (HCC) arising from decompensated hepatitis B virus (HBV)-related cirrhosis. Long-term lamivudine administration improved liver function dramatically despite repeated treatment for HCC. His Child-Pugh score was 9 points at start of lamivudine treatment, improving to 5 points after 1 year. His indocyanine green at 15 min after injection test score was 48% before lamivudine treatment, improving to 22% after 2 years and to 5% after 4 years. Radiofrequency ablation controlled the HCC foci and maintained his liver function. In April 2009, abdominal computed tomography revealed a tumor thrombus in the right portal vein. Since his indocyanine green test results had improved to less than 10%, we performed a right hepatectomy, which was successful. To our knowledge, there have been no documented reports of patients undergoing successful right hepatectomy for HCC arising from decompensated cirrhosis. The findings observed in our patient indicate the importance of nucleoside analogs for treating HBV-related HCC.

Entities:  

Keywords:  Decompensated cirrhosis; Hepatectomy; Hepatitis B virus; Hepatocellular carcinoma; Lamivudine

Mesh:

Substances:

Year:  2012        PMID: 22654459      PMCID: PMC3360460          DOI: 10.3748/wjg.v18.i20.2586

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  34 in total

1.  Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis.

Authors:  D Kapoor; R C Guptan; S M Wakil; S N Kazim; R Kaul; S R Agarwal; S Raisuddin; S E Hasnain; S K Sarin
Journal:  J Hepatol       Date:  2000-08       Impact factor: 25.083

2.  Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus.

Authors:  Shoji Kubo; Hiromu Tanaka; Shigekazu Takemura; Satoshi Yamamoto; Seikan Hai; Tsuyoshi Ichikawa; Shintaro Kodai; Hiroji Shinkawa; Hiroki Sakaguchi; Akihiro Tamori; Daiki Habu; Shuhei Nishiguchi
Journal:  Hepatol Res       Date:  2007-02       Impact factor: 4.288

3.  Efficacy of lamivudine on hepatitis B viral status and liver function in patients with hepatitis B virus-related hepatocellular carcinoma.

Authors:  Ji Hoon Kim; Joong-Won Park; Dong Wook Koh; Woo Jin Lee; Chang-Min Kim
Journal:  Liver Int       Date:  2008-07-24       Impact factor: 5.828

4.  Hepatitis C and B virus infections in hepatocellular carcinoma. Analysis of direct detection of viral genome in paraffin embedded tissues.

Authors:  Y Edamoto; M Tani; T Kurata; K Abe
Journal:  Cancer       Date:  1996-05-01       Impact factor: 6.860

5.  A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

Authors:  C L Lai; R N Chien; N W Leung; T T Chang; R Guan; D I Tai; K Y Ng; P C Wu; J C Dent; J Barber; S L Stephenson; D F Gray
Journal:  N Engl J Med       Date:  1998-07-09       Impact factor: 91.245

6.  Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP).

Authors:  G Realdi; G Fattovich; S Hadziyannis; S W Schalm; P Almasio; J Sanchez-Tapias; E Christensen; G Giustina; F Noventa
Journal:  J Hepatol       Date:  1994-10       Impact factor: 25.083

7.  Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study.

Authors:  Tito Livraghi; Luigi Solbiati; M Franca Meloni; G Scott Gazelle; Elkan F Halpern; S Nahum Goldberg
Journal:  Radiology       Date:  2003-02       Impact factor: 11.105

8.  Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus.

Authors:  Robert Perrillo; Hie-Won Hann; David Mutimer; Bernard Willems; Nancy Leung; William M Lee; Alison Moorat; Stephen Gardner; Mary Woessner; Eric Bourne; Carol L Brosgart; Eugene Schiff
Journal:  Gastroenterology       Date:  2004-01       Impact factor: 22.682

9.  Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

Authors:  Marion G Peters; H w Hann Hw; Paul Martin; E Jenny Heathcote; P Buggisch; R Rubin; M Bourliere; K Kowdley; C Trepo; D f Gray Df; M Sullivan; K Kleber; R Ebrahimi; S Xiong; Carol L Brosgart
Journal:  Gastroenterology       Date:  2004-01       Impact factor: 22.682

10.  A prospective and comparative cohort study on efficacy and drug resistance during long-term lamivudine treatment for various stages of chronic hepatitis B and cirrhosis.

Authors:  Tomohiro Nishida; Haruhiko Kobashi; Shin-Ichi Fujioka; Kozo Fujio; Kouichi Takaguchi; Hiroshi Ikeda; Mitsuhiko Kawaguchi; Masaharu Ando; Yasuyuki Araki; Toshihiro Higashi; Bon Shoji; Akinobu Takaki; Yoshiaki Iwasaki; Kohsaku Sakaguchi; Yasushi Shiratori; Kazuhide Yamamoto
Journal:  J Gastroenterol Hepatol       Date:  2007-12-14       Impact factor: 4.029

View more
  1 in total

Review 1.  Benefits of nucleos(t)ide analog treatments for hepatitis B virus-related cirrhosis.

Authors:  Koichi Honda; Masataka Seike; Kazunari Murakami
Journal:  World J Hepatol       Date:  2015-10-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.